Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression

APMIS

Volumn 104, Issue 9, 1996, Pages 629-639

  Engel, Anne Marie ^a   Svane, Inge Marie ^a   Mouritsen, Søren ^b   Rygaard, Jørgen ^c   Clausen, Jes ^d   Werdelin, Ole ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b M and E A/S   (Denmark)

^c Kommunehospitalet ^*  (Denmark)

^d NOVO NORDISK A S   (Denmark)

Author keywords

MCA tumors; Methylcholanthrene; MHC class I; Nude mice; Sarcomas

Indexed keywords

3 METHYLCHOLANTHRENE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SARCOMA;

EID: 0029957973     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1996.tb04923.x     Document Type: Article

References (43)

1. Austin, F. C., Finerty, J. F. & Sogn, J. A.: Cancer immunology: Highlights of the NCI extramural immunology program. Cancer Invest. 8: 207-228, 1990.
2. Bartlett, G. L.: Effect of host immunity on the antigenic strength of primary tumors. J. Natl. Cancer Inst. 49: 493-504, 1972.
3. Bodmer, W.: A new look at tumor immunology. Eur. J. Cancer 28A: 1761-1762, 1992.
4. Browning, M. & Bodmer, W. F.: MHC antigens and cancer: Implications for T-cell surveillance. Curr. Opin. Immunol. 4: 613-618, 1992.
5. Burnet, F. M.: The concept of immunological surveillance. Progr. Expr. Tumor. Res. 13: 1-27, 1970.
6. Christinck, E. R., Luscher, M. A., Barber, B. H. & Williams, D. B.: Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352: 67-70, 1991.
7. Doherty, P. C., Knowles, B. B. & Wettstein, P. J.: Immunological surveillance of tumors in the context of major histocompatibility complex restriction of T cell function. Adv. Cancer Res. 42: 1-65, 1984.
8. Eisenbach, L., Hollander, N., Greenfeld, L., Yakor, H., Segal, S. & Feldman, M.: The differential expression of H-2 K versus H-2 D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int. J. Cancer 34: 567-573, 1984.
9. Elliott, B. E., Carlow, D. A., Rodricks, A. & Wade, A.: Perspectives on the role of MHC antigens in normal and malignant cell development. Adv. Cancer Res. 53: 181-245, 1989.
10. Foley, E. J.: Antigenic properties of methylchol-anthrene-induced tumors in mice of the strain of origin. Cancer Res. 14: 835-837, 1953.
11. Goodenow, R., Vogel, M. J. & Linsk, R. L.: Histocompatibility antigens on murine tumors. Science 230: 777-783, 1985.
12. Gooding, L. R.: Characterization of a progressive tumor from C3H fibroblasts transformed in vitro with SV40 virus. Immunoresistance in vivo correlates with phenotypic loss of H-2 K. J. Immunol. 129: 1306-1312, 1982.
13. Gopas, J., Rager-Zisman, B., Bar-Eli, M., Hämmerling, G. & Segal, S.: The relationship between MHC antigen expression and metastasis. Adv. Cancer Res. 53: 89-115, 1989.
14. Gopas, J., Rager-Zisman, B., Har-Vardi, I., Hämmerling, G., Bar-Eli, M. & Segal, S.: NK sensitivity, H-2 expression and metastatic potential: analysis of H-2Dk gene transfected fibrosarcoma cells. J. Immunogenet. 16: 305-313, 1989.
15. Greenberg, A. H., Egan, S. E., Jarolin, L., Gingras, M.-C. & Wright, J. A.: Natural killer cell recognition of implantation and early lung growth of H-ras-transformed 10T1/2 fibroblasts in mice. Cancer Res. 47: 4801-4805, 1987.
16. Hanna, N.: The role of natural killer cells in the control of tumor growth and metastasis. Biochim. Biophys. Acta 780: 213-226, 1985.
17. Hanna, N. & Fidler, I. J.: Role of natural killer cells in the destruction of circulating tumor emboli. J. Natl. Cancer Inst. 65: 801-809, 1980.
18. Hui, K. M.: Re-expression of MHC class I molecules on malignant tumor cells and its effect on host-tumor interaction. Bioessays 11: 22-26, 1989.
19. Hui, K. M. & Kim, B. S.: Tumor-specific immunity induced by somatic hybrids. Cell. Immunol. 87: 591-600, 1984.
20. Johnson, S.: The effect of thymectomy and of the dose of 3-methylcholanthrene on the induction and antigenic properties of sarcomas in C57BI mice. Br. J. Cancer 22: 93-104, 1968.
21. Kawano, Y.-I., Taniguchi, K., Toshitani, A. & Nomoto, K.: Synergistic defense system by cooperative natural effectors against metastasis of B16 melanoma cells in H-2 associated control: different behavior of H-2+ and H-2- cells in metastatic processes. J. Immunol. 136: 4729-4734, 1986.
22. Klein, E. & Mantovani, A.: Action of natural killer cells and macrophages in cancer. Curr. Opin. Immunol. 5: 714-718, 1993.
23. Klein, G.: Immune and non-immune control of neoplastic development: Contrasting effects of host and tumour evolution. Cancer 45: 2486-2524, 1980.
24. Lee, D. R.: The murine MHC class I genes, H-2Dq and H-2Lq, are strikingly homologous to each other, H-2Ld, and two genes reported to encode tumour-specific antigens. J. Exp. Med. 168: 1719-1739, 1988.
25. Ljunggren, H. & Kärre, K.: In search of the missing self: MHC molecules and NK recognition. Immunol. Today 11: 237-244, 1990.
26. Moore, M.: Natural immunity to tumors - theoretical predictions and biological observations. Br. J. Cancer 52: 147-151, 1985.
27. Ortaldo, J. R. & Herberman, R. B.: Heterogeneity of natural killer cells. Annu. Rev. Immunol. 2: 359-394, 1984.
28. Outzen, H. C., Custer, R. P., Eaton, G. J. & Prehn, R. T.: Spontaneous and induced tumor incidence in germfree 'nude' mice. J. Reticuloendothelial Soc. 17: 1-9, 1975.
29. Petersen, B. L., Engel, A., Juul-Madsen, H., Mouritsen, S., Svane, I. M. & Werdelin, O.: Tumors developing in nude mice express unusually large amounts of MHC class I antigens. APMIS 99: 1111-1119, 1991.
30. Plaksin, D., Gelber, C., Feldman, M. & Eisenbach, L.: Reversal of the metastatic phenotype in Lewis lung carcinoma cells after transfection with syngeneic H-2Kb gene. Proc. Natl. Acad. Sci. USA 85: 4463-4467, 1988.
31. Prehn, L. M. & Lawler, E. M.: Rank order of sarcoma susceptibility among mouse strains reverses with low concentrations of antigen. Science 204: 309-310, 1979.
32. Prehn, R. T.: Function of depressed immunologic reactivity during carcinogenesis. J. Natl. Cancer Inst. 31: 791-805, 1963.
33. Prehn, R. T.: Relationship of tumor immunogenicity to concentration of the antigen. J. Natl. Cancer Inst. 55: 189-190, 1975.
34. Radzikowski, C., Rygaard, J., Budzynski, W., Stenvang, J. P., Schou, M., Vangsted, A. & Zeuthen, J.: Strain- and age-dependent natural and activated in vitro cytotoxicity in athymic nude mice. APMIS 102: 481-488, 1994.
35. Rygaard, J.: Thymus and self. Immunobiology of the mouse mutant nude. John Wiley, London 1973.
36. Schmidt, W. & Festenstein, H.: Resistance to cell mediated cytotoxicity is correlated with reduction of H-2K gene products in AKR leukemia. Immunogenetics 16: 257-267, 1982.
37. Storkus, W. J. & Dawson, J. R.: Target structures involved in natural killing (NK): Characteristics, distribution and candidate molecules. Immunology 10: 393-416, 1991.
38. Stutman, O.: Tumor development after 3-methylcholanthrene in immunologically deficient athymic nude mice. Science 183: 534-536, 1974.
39. Svane, I. M., Engel, A., Nielsen, M., Ljunggren, H., Rygaard, J. & Werdelin, O.: Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur. J. Immunol. 1996 (in press).
40. Tanaka, K., Isselbacher, K. J., Khoury, G. & Jay, G.: Reversal of oncogenesis by the expression of a major histocompatibility gene. Science 228: 26-30, 1985.
41. Tanaka, K., Yoshioka, T., Biberich, C. & Jay, G.: Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu. Rev. Immunol. 6: 359-380, 1988.
42. Wallich, R., Bulbuc, N., Hämmerling, G., Katzav, S., Segal, S. & Feldman, M.: Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315: 301-305, 1985.
43. Wallny, H., Deres, K., Faath, S., Jung, G., Van Pel, A., Boon, T. & Rammensee, H.: Identification and quantification of a naturally presented peptide as recognized by cytotoxic T lymphocytes specific for an immunogenic tumor variant. Int. Immunol. 4: 1085-1090, 1992.